methyl 4-((phenethylamino)methyl)benzoate | 851365-09-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-((phenethylamino)methyl)benzoate
• 英文别名: Methyl 4-{[(2-phenylethyl)amino]methyl}benzoate；methyl 4-[(2-phenylethylamino)methyl]benzoate
• CAS: 851365-09-8
• 化学式: C₁₇H₁₉NO₂
• 分子量: 269.343
• InChiKey: DFSACDXGVBVPBP-UHFFFAOYSA-N

物化性质

• 沸点：
  405.4±33.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-((phenethylamino)methyl)benzoate 在 羟胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 16.5h， 生成 N-hydroxy-4-((1-phenethyl-3-phenylureido)methyl)benzamide
  参考文献：
  名称：

  Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth

  摘要：

  The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies. In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor. Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compounds bearing a branched linker group results in increased potency and selectivity for HDAC6. Compound 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of similar to 600-fold relative to the inhibition of HDACI. These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth. To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.

  DOI：

  10.1021/jm301098e
• 作为产物：
  描述：

  4-溴甲基苯甲酸甲酯 、 2-苯乙胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以62%的产率得到methyl 4-((phenethylamino)methyl)benzoate
  参考文献：
  名称：

  IAP ANTAGONISTS

  摘要：

  揭示了调节凋亡抑制剂(IAPs)活性的化合物，包含这些化合物的药物组合物以及利用该发明的化合物治疗增生性疾病和失调凋亡疾病（如癌症）的方法。

  公开号：

  US20150238558A1

文献信息

• [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES<br/>[FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE
  申请人：S BIO PTE LTD

  公开号：WO2005040101A1

  公开（公告）日：2005-05-06

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。
• NOVEL COMPOUNDS
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150057298A1

  公开（公告）日：2015-02-26

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 , X, m, R 2 , Y, R 3 , Z, n, R 4 , A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了化合物的公式（I）及其药用盐，其中R1、X、m、R2、Y、R3、Z、n、R4、A和B的定义如规范中所述，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• [EN] AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS AMIDES UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DE L'ACIDE LYSOPHOSPHATIDIQUE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2015025164A1

  公开（公告）日：2015-02-26

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R1. X, m. R2, Y, R3, Z, n, R4. A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了化合物的结构式(I)及其药用盐，式(I)中R1、X、m、R2、Y、R3、Z、n、R4、A和B如规范中定义，以及其制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• [EN] RAF INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE RAF
  申请人：DECIPHERA PHARMACEUTICALS LLC

  公开号：WO2013134298A1

  公开（公告）日：2013-09-12

  This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.

  这项发明提供了化合物的公式(I)或其药用可接受的盐；包括公式(I)化合物的药物组合物；以及使用公式(I)化合物治疗特定癌症。
• [EN] SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS D'HISTONE DÉSACÉTYLASE 6
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2013134467A1

  公开（公告）日：2013-09-12

  Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

  披露了具有化学式（I）的选择性组蛋白去乙酰化酶抑制剂（HDACi）。还披露了制备和使用这些抑制剂用于治疗癌症，特别是黑色素瘤的方法。